Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2
The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).
Leukemia, Myeloid, Acute
BIOLOGICAL: RFUSIN2-AML1|BIOLOGICAL: Donor leukocyte infusion (DLI)|BIOLOGICAL: RFUSIN2-AML1 and donor leukocyte infusion|BIOLOGICAL: RFUSIN2-AML1 and donor leukocyte infusion
Toxicity and safety of the 'AML Cell Vaccine', one year
relapse, leukaemia free survival and overall survival, one year
The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).